We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+23.8%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$376M
AUM Growth
+$23.8M
Cap. Flow
-$13.2M
Cap. Flow %
-3.51%
Top 10 Hldgs %
36.6%
Holding
101
New
12
Increased
44
Reduced
25
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$9.17M
2
PCVX icon
Vaxcyte
PCVX
+$6.2M
3
UTHR icon
United Therapeutics
UTHR
+$4.65M
4
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$4.54M
5
BIIB icon
Biogen
BIIB
+$4.3M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$11.2M
2
WAT icon
Waters Corp
WAT
+$5.96M
3
RCM
R1 RCM Inc. Common Stock
RCM
+$5.16M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$4.24M
5
IQV icon
IQVIA
IQV
+$4.02M

Sector Composition

Rank Sector Weight
1 Healthcare 98.13%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCYC
51
Bicycle Therapeutics
BCYC
$284M
$2.7M 0.72%
91,332
+9,968
+12% +$267K
KRMD icon
52
KORU Medical Systems
KRMD
$152M
$2.58M 0.69%
723,056
+39,590
+6% +$109K
XFOR icon
53
X4 Pharmaceuticals
XFOR
$425M
$2.36M 0.63%
79,185
+47,518
+150% +$2.25M
RXST icon
54
RxSight
RXST
$294M
$2.24M 0.6%
176,421
+9,660
+6% +$117K
NTRA icon
55
Natera
NTRA
$45.5B
$2.15M 0.57%
53,492
-51,709
-49% -$2.13M
MDGL icon
56
Madrigal Pharmaceuticals
MDGL
$12.4B
$2.13M 0.57%
7,341
-14,249
-66% -$1.39M
SLN
57
Silence Therapeutics
SLN
$641M
$2.06M 0.55%
134,842
+7,384
+6% +$96.8K
AXGN icon
58
Axogen
AXGN
$2.67B
$1.9M 0.51%
190,055
-9,945
-5% -$110K
RCUS icon
59
Arcus Biosciences
RCUS
$3.69B
$1.81M 0.48%
87,460
-50,434
-37% -$1.39M
LQDA icon
60
Liquidia Corp
LQDA
$7.01B
$1.71M 0.46%
269,192
+14,740
+6% +$79.2K
COGT icon
61
Cogent Biosciences
COGT
$6.76B
$1.64M 0.44%
141,582
-95,115
-40% -$1.18M
ISEE
62
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.58M 0.42%
73,958
+23,958
+48% +$511K
FULC icon
63
Fulcrum Therapeutics
FULC
$284M
$1.51M 0.4%
206,866
-28,519
-12% -$186K
AGIO icon
64
Agios Pharmaceuticals
AGIO
$2.04B
$1.4M 0.37%
+50,000
New +$1.41M
CGEM icon
65
Cullinan Oncology
CGEM
$1.26B
$1.39M 0.37%
+131,378
New +$1.6M
AKYA
66
DELISTED
Akoya BioSciences
AKYA
$1.35M 0.36%
141,255
-20,446
-13% -$252K
TELA icon
67
TELA Bio
TELA
$32.3M
$1.34M 0.36%
116,668
+6,388
+6% +$57.2K
LFCR icon
68
Lifecore Biomedical
LFCR
$181M
$1.32M 0.35%
203,578
+1,330
+0.7% +$11K
SGHT icon
69
Sight Sciences
SGHT
$456M
$1.28M 0.34%
+105,102
New +$999K
OPNT
70
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$1.22M 0.32%
59,943
-16,587
-22% -$254K
CYTK icon
71
Cytokinetics
CYTK
$10.5B
$1.15M 0.31%
+25,000
New +$1.08M
MIRM icon
72
Mirum Pharmaceuticals
MIRM
$6.04B
$1.03M 0.27%
52,754
+10,359
+24% +$205K
GH icon
73
Guardant Health
GH
$22.2B
$952K 0.25%
+35,000
New +$1.6M
LXRX icon
74
Lexicon Pharmaceuticals
LXRX
$1.05B
$804K 0.21%
421,202
+117,588
+39% +$250K
TKNO icon
75
Alpha Teknova
TKNO
$397M
$725K 0.19%
128,458
+7,034
+6% +$31.2K
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Parkman Healthcare Partners held 101 positions worth $376M, up 6.8% from $352M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Parkman Healthcare Partners withdrew a net $13.2M in Q4 2022, closing 20 positions and reducing 25 holdings. Its most notable exit was CVS Health, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Humana worth $8.93M.

  • Parkman Healthcare Partners's largest Q4 2022 buy was Humana: 17,439 shares worth $8.93M.
  • Parkman Healthcare Partners added most to United Therapeutics in Q4 2022, an estimated $4.65M increase.
  • Parkman Healthcare Partners's biggest Q4 2022 reduction was Waters Corp, cutting an estimated $5.96M.
  • Parkman Healthcare Partners fully exited CVS Health in Q4 2022, selling an estimated $11.2M.
  • Parkman Healthcare Partners's ten largest holdings make up 37% of its $376M portfolio in Q4 2022.
  • Parkman Healthcare Partners opened 12 new positions and closed 20 in Q4 2022.
  • Parkman Healthcare Partners's portfolio value rose 6.8% quarter-over-quarter to $376M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2022, filed 13 Feb 2023.